SavedAdd your journal

Journals / Turkish Journal of Hematology / 2018 / Cilt: 35 - Sayı: 3

Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study

Anemi Diffüz büyük B-hücreli lenfoma Hastalarında Kötü Prognozla İlişkilidir: Tek Merkezli Retrospektif Bir Çalışma

Wataru YAMAMOTO
Kenji MATSUMOTO
Kenji MOTOHASHI
Shin FUJISAWA
Taiki ANDO
Megumi Koyama
Satoshi KOYAMA
Yoshimi ISHII
Ayumi NUMATA
Hideaki NAKAJIMA
Maki HAGIHARA
Pages
181–184
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To determine theprognostic value of hemoglobin (Hb) level in DLBCL patients, weperformed a retrospective study.Materials and Methods: We evaluated disease outcome, progressionfree survival (PFS), overall survival as the endpoint, and clinical andlaboratory factors affecting the outcome of 185 DLBCL patients whohad received rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisolone therapy during 2004-2014.Results: The study group included 121 men and 64 women with amedian age of 66 years minimum-maximum: 21-83 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Useful prognostic biomarkers for diffuse large B-celllymphoma (DLBCL) patients have been reported.
📊
Key Findings & Data:To determine theprognostic value of hemoglobin (Hb) level in DLBCL patients, weperformed a retrospective study.Materials and Methods: We evaluated disease outcome, progressionfree survival (PFS), overall survival as the endpoint, and clinical andlaboratory factors affecting the outcome of 185 DLBCL patients whohad received rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisolone therapy during 2004-2014.Results: The study group included 121 men and 64 women with amedian age of 66 years minimum-maximum: 21-83 years.
💡
Conclusion & Impact:In univariateanalysis, factors independently associated with worse PFS were EasternCooperative Oncology Group performance status ≥2, Ann Arbor stage IIIor IV, anemia with Hb levels of
🔬Design:Research Article
📍Scope:2004-2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Useful prognostic biomarkers for diffuse large B-celllymphoma (DLBCL) patients have been reported. To determine theprognostic value of hemoglobin (Hb) level in DLBCL patients, weperformed a retrospective study.Materials and Methods: We evaluated disease outcome, progressionfree survival (PFS), overall survival as the endpoint, and clinical andlaboratory factors affecting the outcome of 185 DLBCL patients whohad received rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisolone therapy during 2004-2014.Results: The study group included 121 men and 64 women with amedian age of 66 years minimum-maximum: 21-83 years. In univariateanalysis, factors independently associated with worse PFS were EasternCooperative Oncology Group performance status ≥2, Ann Arbor stage IIIor IV, anemia with Hb levels of

Özet

Amaç: Diffüz büyük B hücreli lenfoma (DBBHL) hastaları için yararlı prognostik belirteçler bildirilmiştir. DBBHL hastalarında hemoglobin (Hb) düzeyleri ile prognoz ilişkisini araştırmak amacıyla retrospektif bir çalışma yaptık. Gereç ve Yöntemler: 2004-2014 yılları arasında rituksimab, siklofosfamid, doksorubisin, vinkristin ve prednizolon tedavisi almış olan 185 DBBHL hastasının klinik ve laboratuvar bulguları değerlendirildi ve bunların hastalık sonuçlarına, ilerlemesiz sağkalım (PFS) ve toplam sağkalıma (TS) etkileri araştırıldı. Bulgular: Araştırma grubunda 121 erkek ve 64 kadın vardı, ortanca yaş 66 yıldı (minimum-maksimum: 21-83 yıl). Tek değişkenli analizde Eastern Cooperative Oncology Group performans durumunun ≥2 olması, Ann Arbor evre III veya IV olması ve Hb değerinin

🔖

Cite This Article

YAMAMOTO, W., MATSUMOTO, K., MOTOHASHI, K., FUJISAWA, S., ANDO, T., Koyama, M., KOYAMA, S., ISHII, Y., NUMATA, A., NAKAJIMA, H., HAGIHARA, M. (2022). Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study. Turkish Journal of Hematology, Cilt: 35 - Sayı: 3, 181–184. https://ajindex.com/articles/606755

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
  2. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033. Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res 2011;17:6112-6117. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987- 994. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
  3. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842.
  4. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998;9:1109-1115. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452-458.
  5. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 2009;27:4555-4562. Solal-Celigny P. Follicular Lymphoma International Prognostic Index. Curr Treat Options Oncol 2006;7:270-275. C